Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Other/Resistance

Resistance

68

Pipeline Programs↗

47

Active Trials↗

29

Companies Involved↗

Resistance is a moderately active landscape with 68 programs across 29 companies. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

68/100

Pipeline Velocity

45/100

Mech. Concentration

5/100

Completion Rate

83/100

Attrition Rate

11/100

Pipeline

Programs by Phase

Preclinical46

Albendazole Pill

University Ghent

Non-Steroidal Anti-Inflammatory Drug

GSK

XBD173

Novartis

Finasteride

Organon and Co

E. Coli Strain E1392-75-2A

NIZO Food Research

Phase 111

Olanzapine

MODAG GmbH

[1-13c] Sodium Acetate

Columbia University

[6,6-2h2] D-Glucose

Columbia University

Growth Hormone

Pfizer

Alpelisib

Novartis

Phase 210

Pembrolizumab

Merck & Co.

Third-Generation EGFR-TKI

Hunan Province Tumor Hospital

Orlistat

Engelhard Arzneimittel GmbH & Co.KG

Trastuzumab

Roche

Alectinib

Roche

Phase 31

D-Chiro-Inositol Combined With Metformin

Campus Bio-Medico University

Approved

No programs

Analysis

Modality Breakdown

97%

Small molecule

58 of 60 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 60 classified programs, each share of the total. Modality classified for 97% of 68 pipeline programs.

Analysis

Trial Status

325

clinical trials

Completed199 · 61%

Unknown status39 · 12%

Terminated20 · 6%

Recruiting20 · 6%

Withdrawn17 · 5%

Not yet recruiting14 · 4%

Other16 · 5%

Clinical Trials

Trial Activity

325 trials

Neuromuscular Electrical Stimulation: A Novel Treatment for Improving Metabolism

Recruiting·University of Texas, El Paso·Preclinical·NCT06722391·80 enrolled

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT07318389·100 enrolled

Alpelisib Challenge Test (ACT) for Assessment of Pancreatic β-Cell Reserve, Pilot & Feasibility Study

Recruiting·CColumbia University·Phase 1·NCT07778524·15 enrolled

Human Models of Selective Insulin Resistance: Alpelisib, Part I

Recruiting·CColumbia University·Phase 1·NCT06354088·32 enrolled

Determining Cell- and Spatially-distinct Skeletal Muscle Transcriptional Aberrations With Insulin Resistance

Recruiting·AAdventHealth Translational Research Institute·N/A·NCT07516509·36 enrolled

A Comparison of Neuromuscular Recruitment in Trained and Untrained Adults

Recruiting·MMayo Clinic·N/A·NCT06820658·80 enrolled

The Muscle Phenotype and Cardiometabolic Health Monitoring Project

Recruiting·UUniversity Ghent·N/A·NCT07678736·250 enrolled

Reversal of Lipid-Induced Insulin Resistance

Recruiting·YYale University·Preclinical·NCT02193295·250 enrolled

Investigating the Optimal Management of Dolutegravir Resistance

Recruiting·UUniversity of Nairobi·N/A·NCT06762054·6,600 enrolled

Combined Oral Contraceptive Pill and Resistance Starch

Recruiting·UUniversity of Pennsylvania·Phase 2·NCT06852365·100 enrolled

Ndovu RCT: Investing the Optimal Management of Dolutegravir Resistance

Recruiting·UUniversity of Nairobi·Phase 3·NCT06747507·392 enrolled

The Role of Histamine in Muscle Protein Synthesis Following Resistance Training

Recruiting·UUniversity Ghent·N/A·NCT06152497·50 enrolled

Study on the Mechanism of Acquired Resistance of Entrectinib

Recruiting·FFudan University·N/A·NCT07199959·38 enrolled

Effect of Beta-blockers on Coronary Flow and Resistance in Patients With ANOCA

Recruiting·VVZW Cardiovascular Research Center Aalst·Phase 4·NCT06864234·46 enrolled

5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy

Recruiting·—·N/A·NCT04288427·120 enrolled

Page 1 of 22

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)